Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through debt or equity in the transcript. The company maintains a strong financial position with a negligible Debt Equity Ratio of 0.01. Focus is on optimizing inventory and reducing sundry debtors to support future projects and business prospects. CapEx plans are mainly related to capacity expansion and technology development, but funding sources are not specified as new fundraising. No explicit discussion about raising funds through equity or additional debt during the call.

Future growth expectations in sales/revenue/volumes?

Company expects positive growth in sales and volumes in the current year driven by improved market demand and price realizations. Focus on achieving about 10% profit margins typical for the year. Expansion plans with new capacity additions primarily in the subsequent year. Increased export volumes, especially in manufacturing division, supported by EU and Turkey REACH registrations, boosting exports and revenues. New orders for N-Methylol Acrylamide (NMA) from multinational and domestic customers expected to substantially increase volumes. Commercial launch of Polyacrylamide Solids t

Future growth expectations in earnings/operating earnings/profits/EPS?

The company is striving to achieve about 10% margins for the current year, which aligns with their typical margin levels. Positive revenue growth is expected due to improving market demand and price realizations, particularly from exports and manufacturing divisions. Manufacturing segment shows promise with new EU REACH and Turkey REACH registrations expanding export markets. Capacity expansions are planned, with new manufacturing plants targeted for early FY26, indicating planned future growth. Margins in manufacturing are expected to be better than distribution, supporting higher pro

Current/ Expected Orderbook/ Pending Orders?

The webinar transcript does not disclose specific details about the current or expected order book and pending orders in exact numbers. However, it mentions receiving new orders for N-Methylol Acrylamide (NMA) from a foreign multinational, indicating growth in that product line. Approval from a key domestic customer for NMA is expected soon, which is anticipated to substantially increase volume and sales. Discussions are ongoing for a new specialty chemicals manufacturing project with a key principal at the Jhagadia site. The company has earned two toll manufacturing projects with U.S. and Eur

IN US

Sale is live|00:00:00left today

Black Rose Industries LtdQ2 FY23Chemicals & Petrochemicals

Black Rose Industries Ltd Q2 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹90.2P/E: 21.8Market Cap: ₹491 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

→Company expects positive growth in sales and volumes in the current year driven by improved market demand and price realizations.
→Focus on achieving about 10% profit margins typical for the year.
→Expansion plans with new capacity additions primarily in the subsequent year.
→Increased export volumes, especially in manufacturing division, supported by EU and Turkey REACH registrations, boosting exports and revenues.
→New orders for N-Methylol Acrylamide (NMA) from multinational and domestic customers expected to substantially increase volumes.
→Commercial launch of Polyacrylamide Solids targeted by Q3 FY25, expected to add to revenue streams.
→Despite challenges like Chinese dumping affecting domestic sales, exports and better price realizations should drive growth.
→Emphasis on maximizing revenues and profit over mere capacity utilization for new product lines.
→Overall good growth expected in both distribution and manufacturing divisions compared to previous periods.

Margin guidance

Category 3

→The company is striving to achieve about 10% margins for the current year, which aligns with their typical margin levels.
→Positive revenue growth is expected due to improving market demand and price realizations, particularly from exports and manufacturing divisions.
→Manufacturing segment shows promise with new EU REACH and Turkey REACH registrations expanding export markets.
→Capacity expansions are planned, with new manufacturing plants targeted for early FY26, indicating planned future growth.
→Margins in manufacturing are expected to be better than distribution, supporting higher profitability.
→Despite current sector distress and pricing pressures, the company anticipates better price realizations towards the end of the quarter and subsequent periods.
→Overall EBITDA improved significantly from 4.5% to 8.84% in recent quarter, with expectations to maintain or improve margins going forward.
→The company foresees strong growth in volumes and revenues, especially in acrylamide-related products and downstream derivatives.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or planned fundraising through debt or equity in the transcript.
→The company maintains a strong financial position with a negligible Debt Equity Ratio of 0.01.
→Focus is on optimizing inventory and reducing sundry debtors to support future projects and business prospects.
→CapEx plans are mainly related to capacity expansion and technology development, but funding sources are not specified as new fundraising.
→No explicit discussion about raising funds through equity or additional debt during the call.

Order book

→The webinar transcript does not disclose specific details about the current or expected order book and pending orders in exact numbers.
→However, it mentions receiving new orders for N-Methylol Acrylamide (NMA) from a foreign multinational, indicating growth in that product line.
→Approval from a key domestic customer for NMA is expected soon, which is anticipated to substantially increase volume and sales.
→Discussions are ongoing for a new specialty chemicals manufacturing project with a key principal at the Jhagadia site.
→The company has earned two toll manufacturing projects with U.S. and European companies.
→Export sales are strengthening due to EU REACH and Turkey REACH registrations, supporting order inflow.
→Overall, growth in orders is expected, especially in distribution and manufacturing divisions, but no exact figures are provided.

Capex plans

Yes

- The company is developing new technology for Polyacrylamide Solids with a target commercial launch by Q3 FY25; CapEx estimated between ₹60 to ₹100 crores depending on finalized technology and equipment sourcing. - A specialty chemical manufacturing project in collaboration with a Japanese principal is in advanced discussion; no fresh land purchase needed, site identified at Jhagadia. - Toll manufacturing projects for U.S. and European companies in acrylamide-related products are underway, requiring additional CapEx. - Facility for manufacturing carboxylic acid is already available; only process/technology development is needed, involving no capital investment. - New capacity additions for other products are expected in subsequent years; current year focuses on market demand and price improvements. - CapEx is planned but balanced against margins and market realities; typical target margin of about 10% for the year. Overall, strategic investments focus on expanding manufacturing capabilities in specialty chemicals and related products with moderate CapEx and leveraging existing infrastructure.

How does Black Rose Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Black Rose Industries Ltd

Rev 4Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Black Rose Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio